Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Diagnosis and management of antibody-mediated rejection: current status and novel approaches.Am J Transplant. 2014; 14: 255-271
- Antibodies in transplantation: the effects of HLA and non-HLA antibody binding and mechanisms of injury.Methods Mol Biol. 2013; 1034: 41-70
- Banff 2011 meeting report: new concepts in antibody-mediated rejection.Am J Transplant. 2012; 12: 563-570
- Acute antibody-mediated rejection in kidney transplant recipients.Transplant Rev (Orlando). 2017; 31: 47-54
- Outcome of antibody-mediated rejection compared to acute cellular rejection after pediatric heart transplantation.Pediatr Transplant. 2018; 22
- Antibody-mediated rejection in the cardiac allograft: diagnosis, treatment and future considerations.Curr Opin Cardiol. 2017; 32: 326-335
- Guidelines for the diagnosis of antibody-mediated rejection in pancreas allografts-updated Banff grading schema.Am J Transplant. 2011; 11: 1792-1802
- Diagnosis of early pancreas graft failure via antibody-mediated rejection: single-center experience with 256 pancreas transplantations.Am J Transplant. 2014; 14: 936-942
- Posttransplant donor-specific anti-HLA antibodies negatively impact pancreas transplantation outcome.Am J Transplant. 2011; 11: 2737-2746
- De novo donor-specific HLA antibodies are associated with early and high-grade bronchiolitis obliterans syndrome and death after lung transplantation.J Heart Lung Transplant. 2014; 33: 1288-1294
- Antibody-mediated rejection in lung transplantation.Curr Transplant Rep. 2015; 2: 316-323
- De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients.Am J Transplant. 2013; 13: 1541-1548
- Prevalence and clinical impact of donor-specific alloantibody among intestinal transplant recipients.Transplantation. 2017; 101: 873-882
- Updates on antibody-mediated rejection in intestinal transplantation.World J Transplant. 2016; 6: 564-572
- FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. Food and Drug Administration (US).National Institute of Health, Bethesda (MD)2016
- Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies.Kidney Int. 2017; 91: 729-737
- Antibody-mediated rejection of the lung: a consensus report of the International Society for Heart and Lung Transplantation.J Heart Lung Transplant. 2016; 35: 397-406
- Acute antibody-mediated rejection after intestinal transplantation.World J Transplant. 2016; 6: 719-728
- Pros and cons for C4d as a biomarker.Kidney Int. 2012; 81: 628-639
- Report from a consensus conference on antibody-mediated rejection in heart transplantation.J Heart Lung Transplant. 2011; 30: 252-269
- The presence of anti-HLA donor-specific antibodies in lung allograft recipients does not correlate with C4d immunofluorescence in transbronchial biopsy specimens.Arch Pathol Lab Med. 2014; 138: 1053-1058
- Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions.Am J Transplant. 2014; 14: 272-283
- Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies.Am J Transplant. 2009; 9: 2561-2570
- Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes.J Heart Lung Transplant. 2009; 28: 417-422
- Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection.J Heart Lung Transplant. 2009; 28: 781-784
- Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies.J Clin Invest. 2017; 127: 2492-2504
- Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss.J Am Soc Nephrol. 2015; 26: 457-467
- C4d fixing, luminex binding antibodies - a new tool for prediction of graft failure after heart transplantation.Am J Transplant. 2007; 7: 2809-2815
- Complement-binding anti-HLA antibodies and kidney-allograft survival.N Engl J Med. 2013; 369: 1215-1226
- Identifying subphenotypes of antibody-mediated rejection in kidney transplants.Am J Transplant. 2016; 16: 908-920
- Impact of IgM and IgG3 anti-HLA alloantibodies in primary renal allograft recipients.Transplantation. 2014; 97: 494-501
- Impact of IgG3 subclass and C1q-fixing donor-specific HLA alloantibodies on rejection and survival in liver transplantation.Am J Transplant. 2015; 15: 1003-1013
- Compartment-specific expression of natural killer cell markers in renal transplantation: immune profile in acute rejection.Transpl Int. 2016; 29: 443-452
- HLA class I antibody-mediated endothelial and smooth muscle cell activation.Curr Opin Organ Transplant. 2012; 17: 446-451
- Impact of donor-specific antibodies on results of liver transplantation.Curr Opin Organ Transplant. 2013; 18: 279-284
- The role of donor-specific HLA alloantibodies in liver transplantation.Am J Transplant. 2014; 14: 779-787
- Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation.Am J Transplant. 2008; 8: 324-331
- Impact of pretransplant anti-HLA antibodies on outcomes in lung transplant candidates.Am J Respir Crit Care Med. 2014; 189: 1234-1239
- Early donor-specific antibodies in lung transplantation: risk factors and impact on survival.J Heart Lung Transplant. 2014; 33: 1255-1263
- Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss.Am J Transplant. 2009; 9: 1063-1071
- Beyond histology: lowering human leukocyte antigen antibody to improve renal allograft survival in acute rejection.Transplantation. 2010; 89: 962-967
- Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection.Am J Transplant. 2009; 9: 1099-1107
- Monitoring and treating posttransplant human leukocyte antigen antibodies.Hum Immunol. 2009; 70: 655-659
- Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation.J Heart Lung Transplant. 2010; 29: 973-980
- Late antibody-mediated rejection after heart transplantation following the development of de novo donor-specific human leukocyte antigen antibody.Transplantation. 2012; 93: 650-656
- Pre-empting antibody-mediated rejection: a program of DSA monitoring and treatment can effectively prevent antibody mediated rejection.Clin Transplant. 2016; 32: 93-101
- Impact of donor specific HLA antibody monitoring after kidney transplantation.Clin Transplant. 2014; : 143-151
- Human leukocyte antigens antibodies after lung transplantation: primary results of the HALT study.Am J Transplant. 2018; 18: 2285-2294
- Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection.Transplantation. 2009; 87: 1837-1841
- Current outcomes of chronic active antibody mediated rejection - a large single center retrospective review using the updated BANFF 2013 criteria.Hum Immunol. 2016; 77: 346-352
- Subclinical rejection phenotypes at 1 year post-transplant and outcome of kidney allografts.J Am Soc Nephrol. 2015; 26: 1721-1731
- Quantifying renal allograft loss following early antibody-mediated rejection.Am J Transplant. 2015; 15: 489-498
- Surveillance of alloantibodies after transplantation identifies the risk of chronic rejection.Kidney Int. 2011; 79: 1131-1137
- Acute antibody-mediated rejection after lung transplantation.J Heart Lung Transplant. 2013; 32: 1034-1040
- Preemptive treatment of early donor-specific antibodies with IgA- and IgM-enriched intravenous human immunoglobulins in lung transplantation.Am J Transplant. 2018; 18: 2295-2304
- Sensitization in transplantation: assessment of risk (STAR) 2017 working group meeting report.Am J Transplant. 2018; 18: 1604-1614
- Survival in sensitized lung transplant recipients with perioperative desensitization.Am J Transplant. 2015; 15: 417-426
- Using real data for a virtual crossmatch.Hum Immunol. 2009; 70: 574-579
- Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation.J Am Soc Nephrol. 2010; 21: 1398-1406
- The role of donor-specific antibodies in acute cardiac allograft dysfunction in the absence of cellular rejection.Transplantation. 2014; 98: 229-238
- The use of circulating donor specific antibody to predict biopsy diagnosis of antibody-mediated rejection and to provide prognostic value after heart transplantation in children.J Heart Lung Transplant. 2016; 35: 179-185
- Renal transplant patients biopsied for cause and tested for C4d, DSA, and IgG subclasses and C1q: which humoral markers improve diagnosis and outcomes?.J Immunol Res. 2017; 2017: 1652931
- Impact of preformed donor-specific antibodies against HLA class I on kidney graft outcomes: comparative analysis of exclusively anti-Cw vs anti-A and/or -B antibodies.World J Transplant. 2016; 6: 689-696
- Pre-transplant donor HLA-specific antibodies: characteristics causing detrimental effects on survival after lung transplantation.J Heart Lung Transplant. 2014; 33: 1074-1082
- Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation.Nephrol Dial Transplant. 2012; 27: 1231-1238
- Clinical outcomes among renal transplant recipients with pre-transplant weakly reactive donor-specific antibodies.Clin Transplant. 2014; 28: 127-133
- Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis.Kidney Int. 2017; 92: 729-742
- Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: a systematic review and meta-analysis.PLoS Med. 2018; 15: e1002572
- The kinetics of anti-HLA antibodies in the first year after kidney transplantation: in whom and when should they be monitored?.J Transplant. 2018; 2018: 8316860
- De-novo donor-specific anti-HLA antibodies 30 days after lung transplantation are associated with a worse outcome.J Heart Lung Transplant. 2016; 35: 1067-1077
- Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.Nephrol Dial Transplant. 2017; 32: 730-737
- Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.Transplantation. 2013; 95: 410-417
- The synergistic effect of class II HLA epitope-mismatch and nonadherence on acute rejection and graft survival.Am J Transplant. 2015; 15: 2197-2202
- Posttransplant monitoring of de novo human leukocyte antigen donor-specific antibodies in kidney transplantation.Curr Opin Organ Transplant. 2013; 18: 470-477
- Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody.Am J Transplant. 2015; 15: 2921-2930
- Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant.Am J Transplant. 2012; 12: 1157-1167
- Development and impact of De Novo Anti-HLA antibodies in pediatric heart transplant recipients.Am J Transplant. 2015; 15: 2215-2222
- De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival.Am J Transplant. 2011; 11: 312-319
- Donor-specific HLA alloantibodies: impact on cardiac allograft vasculopathy, rejection, and survival after pediatric heart transplantation.J Heart Lung Transplant. 2016; 35: 87-91
- Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after heart transplantation.Ann Saudi Med. 2018; 38: 97-104
- De Novo DQ donor-specific antibodies are associated with chronic lung allograft dysfunction after lung transplantation.Am J Respir Crit Care Med. 2016; 194: 596-606
- Acute rejection and antibody-mediated rejection in lung transplantation.Clin Chest Med. 2017; 38: 667-675
- Antibody-mediated rejection in lung transplantation: clinical outcomes and donor-specific antibody characteristics.Am J Transplant. 2016; 16: 1216-1228
- Characteristics of donor-specific antibodies associated with antibody-mediated rejection in lung transplantation.Front Med (Lausanne). 2017; 4: 155
- Donor-specific and -nonspecific HLA antibodies and outcome post lung transplantation.Eur Respir J. 2017; 50
- HLA matching at the eplet level protects against chronic lung allograft dysfunction.Am J Transplant. 2016; 16: 2695-2703
- HLA-A, -B, -C, -DR, and -DQ matching in pancreas transplantation: effect on graft rejection and survival.Am J Transplant. 2016; 16: 2401-2412
- Antibody mediated rejection due to de-novo DSA causing venous thrombosis of pancreas allograft - a case report.Transpl Immunol. 2018; 47: 22-25
- Preformed and de novo donor specific antibodies in visceral transplantation: long-term outcome with special reference to the liver.Am J Transplant. 2012; 12: 3047-3060
- Immune monitoring in small bowel transplantation.Curr Opin Organ Transplant. 2010; 15: 349-356
- Immunologic challenges in small bowel transplantation.Am J Transplant. 2012; 12: S2-S8
- Antibody-mediated rejection in pediatric small bowel transplantation: capillaritis is a major determinant of C4d positivity in intestinal transplant biopsies.Am J Transplant. 2018; 18: 2250-2260
- Acquisition of C3d-binding activity by de novo donor-specific HLA antibodies correlates with graft loss in nonsensitized pediatric kidney recipients.Am J Transplant. 2016; 16: 2106-2116
- Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients.J Heart Lung Transplant. 2011; 30: 158-163
- C1q test for identification of sensitized liver recipients at risk of early acute antibody-mediated rejection.Ann Transplant. 2017; 22: 518-523
- Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study.Transplantation. 2010; 89: 1403-1410
- Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients.Transplantation. 2008; 86: 1214-1221
- Higher calcineurin inhibitor levels predict better kidney graft survival in patients with de novo donor-specific anti-HLA antibodies: a cohort study.Transpl Int. 2017; 30: 502-509
- Deconstructing interstitial fibrosis and tubular atrophy: a step toward precision medicine in renal transplantation.Kidney Int. 2017; 92: 553-555
- Clinical relevance of HLA antibody monitoring after kidney transplantation.J Immunol Res. 2014; 2014: 845040
- Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation.Transplantation. 2013; 95: 19-47
- Of cells and microparticles: assets and liabilities of HLA antibody detection.Transplantation. 2018; 102: S1-S6
- Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA.Am J Transplant. 2013; 13: 1859-1870
- HLA diagnostics: evaluating DSA strength by titration.Transplantation. 2018; 102: S23-S30
- Using HLA antibody detection, monitoring, and treatment to improve long-term allograft survival.Clin Transplant. 2010; : 317-322
- Summarizing the use of donor specific anti-HLA antibody monitoring in transplant patients.Clin Transplant. 2011; : 333-336
- Donor-specific anti-HLA antibody monitoring and removal in solid organ transplant recipients.Clin Transplant. 2011; : 319-325
- Post-transplant DSA monitoring may predict antibody-mediated rejection in sensitized kidney transplant recipients.Clin Transplant. 2011; : 389-394
- Immune monitoring of kidney allografts.Am J Kidney Dis. 2012; 60: 629-640
- Value of donor-specific anti-HLA antibody monitoring and characterization for risk stratification of kidney allograft loss.J Am Soc Nephrol. 2017; 28: 702-715
- Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA-drilling down on key sources of variation.Am J Transplant. 2013; 13: 3050-3051
- Conformational variants of the individual HLA-I antigens on luminex single antigen beads used in monitoring HLA antibodies: problems and solutions.Transplantation. 2017; 101: 764-777
- The impact of screening method on HLA antibody detection before and after lung transplantation: a prospective pilot study.J Heart Lung Transplant. 2018; 37: 531-533
- Technical aspects of HLA antibody testing.Curr Opin Organ Transplant. 2013; 18: 455-462
- Polyreactive natural antibodies in transplantation.Curr Opin Organ Transplant. 2017; 22: 8-13
- Understanding solid-phase HLA antibody assays and the value of MFI.Hum Immunol. 2017; 78: 471-480
- Clinically relevant interpretation of solid phase assays for HLA antibody.Curr Opin Organ Transplant. 2016; 21: 453-458
- Clinical impact of preformed donor-specific denatured class I HLA antibodies after kidney transplantation.Clin Transplant. 2015; 29: 393-402
- Evaluation of the iBeads assay as a tool for identifying class I HLA antibodies.Hum Immunol. 2015; 76: 651-656
- Deciphering allogeneic antibody response against native and denatured HLA epitopes in organ transplantation.Eur J Immunol. 2015; 45: 2111-2121
- Practical value of identifying antibodies to cryptic HLA epitopes in cardiac transplantation.J Heart Lung Transplant. 2014; 33: 713-720
- Antibodies against denatured HLA class II molecules detected in luminex-single antigen assay.Hum Immunol. 2013; 74: 1300-1303
- 2012 annual literature review of donor-specific HLA antibodies after organ transplantation.Clin Transplant. 2012; : 207-217
- Heart transplantation with donor-specific antibodies directed toward denatured HLA-A*02:01: a case report.Hum Immunol. 2011; 72: 1045-1048
- Donor-specific antibody against denatured HLA-A1: clinically nonsignificant?.Hum Immunol. 2011; 72: 492-498
- Are complement-fixing antibodies against denatured HLA antigens clinically relevant?.Exp Mol Pathol. 2016; 100: 532-533
- Evidence to support a contribution of polyreactive antibodies to HLA serum reactivity.Transplantation. 2016; 100: 217-226
- Complement-fixing antibodies against denatured HLA and MICA antigens are associated with antibody mediated rejection.Exp Mol Pathol. 2016; 100: 45-50
- Detection and clinical impact of human leukocyte antigen antibodies in lung transplantation: a systematic review and meta-analysis.HLA. 2018; 91: 102-111
- Differential modulation of donor-specific antibodies after B-cell depleting therapies to cure chronic antibody mediated rejection.Transplantation. 2015; 99: 63-68
- Eculizumab for the treatment of severe antibody-mediated rejection: a case report and review of the literature.Case Rep Transplant. 2016; 2016: 9874261
- Prognostic tools to assess candidacy for and efficacy of antibody removal therapy.Am J Transplant. 2018; ([Epub ahead of print])
- Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial.Trials. 2014; 15: 107
- Bortezomib-based antibody-mediated rejection therapy and simultaneous conversion to belatacept.Transplantation. 2014; 97: e30-e32
- HLA desensitization with bortezomib in a highly sensitized pediatric patient.Pediatr Transplant. 2014; 18: E280-E282
- Differential effect of bortezomib on HLA class I and class II antibody.Transplantation. 2014; 98: 660-665
- Use of bortezomib as anti-humoral therapy in kidney transplantation.J Korean Med Sci. 2014; 29: 648-651
- Bortezomib use in a pediatric cardiac transplant center.Pediatr Transplant. 2014; 18: 469-476
- A phased desensitization protocol with rituximab and bortezomib for highly sensitized kidney transplant candidates.Transplant Direct. 2015; 1: e17
- The effect of bortezomib on antibody-mediated rejection after kidney transplantation.Yonsei Med J. 2015; 56: 1638-1642
- Assessing antibody strength: comparison of MFI, C1q, and titer information.Am J Transplant. 2015; 15: 2421-2430
- Complement-binding anti-HLA antibodies are independent predictors of response to treatment in kidney recipients with antibody-mediated rejection.Kidney Int. 2018; 94: 773-787
Article info
Publication history
Published online: December 17, 2018
Footnotes
Disclosure: The author has nothing to disclose.
Identification
Copyright
© 2018 Elsevier Inc. All rights reserved.
